Neurocrine Biosciences
NBIX
#1241
Rank
NZ$25.97 B
Marketcap
$256.55
Share price
0.94%
Change (1 day)
14.38%
Change (1 year)
Neurocrine Biosciences is an American biopharmaceutical company that develops treatments for neurological and endocrine-related diseases and disorders.

EPS for Neurocrine Biosciences (NBIX)

EPS in 2023 (TTM): $3.22

According to Neurocrine Biosciences 's latest financial reports the company's current EPS (TTM) is $3.51. In 2022 the company made an earnings per share (EPS) of $2.88 an increase over its 2021 EPS that were of $1.70.

EPS history for Neurocrine Biosciences from 1997 to 2023

Annual EPS

Year EPS Change
2023 (TTM)$3.2211.76%
2022$2.8869.47%
2021$1.70-78.21%
2020$7.81990%
2019$0.7281.82%
2018$0.39-113.5%
2017-$2.920.62%
2016-$2.9057.28%
2015-$1.8425.61%
2014-$1.4718.84%
2013-$1.24-1085.71%
2012$0.13-89.71%
2011$1.22-500%
2010-$0.30-86.92%
2009-$2.33-43.48%
2008-$4.12-57.8%
2007-$9.7692.58%
2006-$5.07371.67%
2005-$1.07-52.76%
2004-$2.2736.56%
2003-$1.67-70%
2002-$5.55118.31%
2001-$2.548.4%
2000-$2.3548.86%
1999-$1.58-20%
1998-$1.97-479.31%
1997$0.52

EPS for similar companies or competitors

Company EPS EPS differencediff. Country
$3.74 6.63%๐Ÿ‡บ๐Ÿ‡ธ USA
$0.98-71.94%๐Ÿ‡ฌ๐Ÿ‡ง UK
-$5.30-251.02%๐Ÿ‡บ๐Ÿ‡ธ USA
$9.72 177.00%๐Ÿ‡บ๐Ÿ‡ธ USA
$6.59 87.79%๐Ÿ‡บ๐Ÿ‡ธ USA
$3.33-5.10%๐Ÿ‡บ๐Ÿ‡ธ USA
-$0.84-123.98%๐Ÿ‡บ๐Ÿ‡ธ USA
-$5.43-254.59%๐Ÿ‡บ๐Ÿ‡ธ USA